You are here

II Clinic of Radiotherapy and Chemotherapy

Prof. Rafał Suwiński, PhD, MD




Secretariat: +48 32 278 88 05
Registration: +48 32 278 81 06/07


II Clinic of  Radiotherapy and Chemotherapy specializes in treatment of lung and other cancers of the chest, gastrointestinal tract, urinary tract, and male genital tract cancers.  The team includes radiation oncologists, clinical oncologists and psychologists.  To optimize the lung cancer diagnostic and therapeutic process we routinely consult our cases with thoracic surgeons by means of a teleconference with the Thoracic Surgery Clinic in Zakopane.  We provide radiotherapy, chemo-radiotherapy and stereotactic radiotherapy – the modern method of early lung cancer treatment in inoperable patients.  The Clinic has extensive experience in prostate cancer:  for early stage patients we choose treatment by CyberKnife; for patients presenting advanced stage prostate cancer we apply combined treatment of brachytherapy and radiotherapy.  One of our major fields of research is perfecting rectal cancer treatment by means of preoperative radiotherapy or radiochemotherapy in close cooperation with the Surgery Clinic of our Institute.  We routinely treat anal cancers and unresectable esophageal cancers applying concurrent chemoradiotherapy.  We use systemic treatment with both cytostatics and molecular target chemotherapy.
Teleradiotherapy represents a preferred form of treatment, i.e. treatment with ionizing radiation from a source located outside the patient’s body.  Stereotactic radiotherapy is a special type of such a therapy – a modern method of irradiation delivered by, among others, CyberKnife.  Radiotherapy is usually combined with surgical treatment, chemotherapy or hormonal therapy in various modalities.  Depending on clinical indications, different methods may be used, such as radical radiotherapy, preoperative or postoperative radiotherapy, radical chemoradiotherapy, preoperative or postoperative, and radiotherapy combined with hormonal therapy or radiotherapy combined with brachytherapy.  Whenever clinically justified, radiotherapy planning is aided by PET-CT imaging to improve treatment accuracy.  More detailed information about the treatment techniques may be found by going to the website of  the Outpatient Radiotherapy Clinic with which we closely cooperate.
Oncologic treatment may cause various side effects, specific to each method and tumor localization.  During the patient’s hospital stay, doctors make daily rounds and the patients also remain under the constant care of our nursing team.  Patients may suffer nausea, loss of body weight, general weakness, immunodeficiency as well as problems with the digestive, pulmonary or urinary tract.  The implemented treatment typically alleviates the symptoms in most patients; however, taking into consideration how stressful oncologic treatment may be, patients are also offered psychological support

Major Achievements:    

  • Implementation of modern radiation techniques in lung cancer treatment (4D radiotherapy, CyberKnife, tumor tracking, radiotherapy 3D with PET-CT planning),
  • In cooperation with the Outpatient Brachytherapy Clinic, clinical implementation of combined teleradiotherapy and brachytherapy in patients with locally advanced prostate cancer.
  • Optimization of rectal cancer preoperative treatment.
  • Implementation of PET-CT based IMRT radiotherapy planning in anal cancer patients.
  • In cooperation with the Translational Research Centre, clinical implementation of modern predictive methods in radiotherapy and chemotherapy.

Major Fields of Research: 
  • Optimization of lung cancer treatment by PET-CT based radiotherapy planning.
  • Non-conventional radiation dose fractionation in lung cancer radiotherapy.
  • Use of cytostatics as radiosensitizers during concurrent radiochemotherapy.
  • Implementation of modern conformal radiotherapy techniques.
  • Non-conventional dose fractionation in prostate cancer.
  • Novel prognostic molecular markers in prostate cancer - in cooperation with the Translational Research Centre

Medical projects:
  1. Validation and implementation of prognostic and predictive proteomic, biochemical, and molecular signatures for individualization and optimization conformal radiotherapy with concurrent chemotherapy in patients with stage IIIAN2 and IIIB non-small cell lung cancer.
  2. Identification of predictive biochemical and molecular signatures for individualization and perioperative radiotherapy and chemotherapy optimization in patients with locally advanced rectal cancer. 
  3. Molecular prognostics, predictive markers, and functional methods of NMR imaging as a tool for rationalization of choosing between conformal teleradiotherapy, teleradiotherapy combined with brachytherapy, or teleradiotherapy combined with stereotactic radiotherapy in patients with intermediate and high-risk prostate cancer:  feed-back trial randomized clinical research.